Methods and compositions for treatment of HSV-2 infections and conditions
US5922328A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Sep 6, 1996 |
| Grant date | Jul 13, 1999 |
| Priority date | — |
| Expiry date | Sep 6, 2016 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2710/16622
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A live, attenuated HSV-2 virus and methods of making and using the virus are provided. The live, attenuated HSV-2 virus is constructed using recombinant techniques and can be used in a pharmaceutical composition for prophylactic treatment of HSV-2 infections and for treatment of recurrent HSV-2 related diseases and conditions. Additionally, a plasmid vector is disclosed for expressing a GST-UL56 fusion protein wherein the protein comprises the Glutathione S Transferase gene product fused to at least an immunogenic portion of the HSV-2 UL56 gene product. The GST-UL56 fusion protein can be used to produce polyclonal antisera to the HSV-2 UL56 gene product, to detect whether recombinant HSV-2 deletion mutants express UL56, and as a type-specific reagent capable of discerning HSV-1 from HSV-2.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.